TB Risk Factors & Progression Risk

· TB Diagnostic Strategies & Cost-Effectiveness

• Varies based on HIV prevalence, drug resistance, and healthcare access.
• Discrete-event simulation (DES) helps assess MDR-TB diagnostics.
• DES tool enhances decision-making in resource-limited settings.
• Incorporating disease transmission models improves predictions.

· Novel TB Vaccines & Impact

• Delay beyond 2025 could reduce effectiveness.
• Adolescent/adult-targeted vaccines may prevent 44M cases & 5M deaths by 2050.
• Accelerated rollout could prevent 65.5M cases & 7.9M deaths.
• Greatest impact in Africa, South-East Asia, and low-income nations.
• High-efficacy, long-lasting vaccines could cut TB mortality by 27%.
• Urgency for policymakers to fast-track vaccine introduction.

· TB & Air Pollution (PM2.5 Exposure)

• PM2.5 linked to higher MDR-TB infection risk and lung damage.
• Different exposure durations impact radiographic severity.
• Smoking, indoor air pollution, and biomass fuel use increase TB risk.
• Air pollution’s TB impact may be underestimated due to socioeconomic factors.

· Household & Environmental Risk Factors

• Solid fuel use contributes to TB risk but evidence remains weak.
• Fine particles, nitrogen oxides, and CO exposure linked to TB.
• Tobacco taxes could fund TB control and clean energy programs.

· Latent TB Infection (LTBI) & Progression Risk

• WHO guidelines prioritize high-risk groups for screening & treatment.
• 11 key risk populations include HIV-positive individuals, healthcare workers, and prisoners.
• Preventive treatment is crucial in the absence of an effective TB vaccine.

· TB Risk Factors by Health Condition

• Corticosteroids: Highest risk when used 30 days before TB diagnosis.
• Diabetes: TB risk 2.33x higher.
• Glomerular Diseases: TB risk 23.36x higher.
• HCV Infection: Higher risk in untreated cases (HR 2.9).
• Cancer: Children with cancer have a 16.82x higher TB risk.
• Rheumatoid Arthritis & Psoriasis: Increased risk with corticosteroid use.
• Vitamin D Deficiency: 5.68x higher risk of progressing to active TB.

See also: Lin TB Lab

Feasible TB Intervention Suggestions

1. Expand Rapid Diagnostic Tools: Increase access to cost-effective and rapid TB diagnostic methods like GeneXpert in resource-limited settings. Implement discrete-event simulation (DES) models to optimize diagnostic strategies for MDR-TB.
2. Accelerate TB Vaccine Development & Rollout: Prioritize fast-track introduction of novel TB vaccines to prevent millions of cases and deaths. Focus on high-burden regions (Africa, South-East Asia) and at-risk populations (adolescents, adults).
3. Strengthen Air Pollution Control Policies: Enforce air quality regulations to reduce PM2.5 and other TB-aggravating pollutants. Promote clean energy solutions (e.g., LPG, electricity) over biomass fuel for cooking and heating.
4. Enhance LTBI Screening & Preventive Treatment: Implement systematic LTBI screening in high-risk groups (HIV-positive individuals, healthcare workers, prisoners). Expand access to preventive therapy (e.g., isoniazid, rifapentine) to reduce progression to active TB.
5. Integrate TB Control into Non-Communicable Disease (NCD) Programs: Strengthen TB screening in diabetes, cancer, and immunosuppressed patients, given their increased TB risk. Provide corticosteroid alternatives or monitor TB risk in patients requiring immunosuppressants.
6. Tax & Regulate Tobacco to Reduce TB Risk: Increase tobacco taxes to discourage smoking, a major TB risk factor. Use tax revenue to fund TB treatment and prevention programs in low-income communities.
7. Improve TB Awareness & Health Education: Conduct public health campaigns on TB transmission, symptoms, and prevention. Educate healthcare workers on early TB detection, drug-resistant TB, and infection control practices.

References:

1. Langley, I., Doulla, B., Lin, H.H., Millington, K. and Squire, B., 2012. Modelling the impacts of new diagnostic tools for tuberculosis in developing countries to enhance policy decisions. Health care management science, 15, pp.239-253.
2. Clark, R.A., Mukandavire, C., Portnoy, A., Weerasuriya, C.K., Deol, A., Scarponi, D., Iskauskas, A., Bakker, R., Quaife, M., Malhotra, S. and Gebreselassie, N., 2023. The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study. The Lancet Global Health, 11(4), pp.e546-e555.
3. Makrufardi, F., Chuang, H.C., Suk, C.W., Lin, Y.C., Rusmawatiningtyas, D., Murni, I.K., Arguni, E., Chung, K.F. and Bai, K.J., 2024. Particulate matter deposition and its impact on tuberculosis severity: A cross-sectional study in Taipei. Science of the Total Environment, 924, p.171534.
4. Lin, H.H., Suk, C.W., Lo, H.L., Huang, R.Y., Enarson, D.A. and Chiang, C.Y., 2014. Indoor air pollution from solid fuel and tuberculosis: a systematic review and meta-analysis. The International journal of tuberculosis and lung disease, 18(5), pp.613-621.
5. Lai, T.C., Chiang, C.Y., Wu, C.F., Yang, S.L., Liu, D.P., Chan, C.C. and Lin, H.H., 2016. Ambient air pollution and risk of tuberculosis: a cohort study. Occupational and environmental medicine, 73(1), pp.56-61.
6. Lin, H.H., Murray, M., Cohen, T., Colijn, C. and Ezzati, M., 2008. Effects of smoking and solid-fuel use on COPD, lung cancer, and tuberculosis in China: a time-based, multiple risk factor, modelling study. The Lancet, 372(9648), pp.1473-1483.
7. Bigio, J., Viscardi, A., Gore, G., Matteelli, A. and Sulis, G., 2023. A scoping review on the risk of tuberculosis in specific population groups: can we expand the World Health Organization recommendations?. European Respiratory Review, 32(167).

TBC 042 

Clinical and Technological Advancements in TB Management

1. Cellular and Molecular Mechanisms in TB-DM Comorbidity

• Cellular Immunology: TB-DM interaction impairs immune cell function, especially macrophages and T cells, diminishing cytokine signaling and immune responses.
• Genomics: Genetic variants (e.g., IL-6 and IL-18 polymorphisms) increase TB-DM susceptibility, paving the way for personalized medicine.
• Transcriptomics: TB-DM exhibits unique gene expression patterns associated with chronic inflammation, especially in neutrophil and innate immune pathways.
• Proteomics: Altered protein expression in TB-DM patients reveals potential biomarkers, including elevated complement and coagulation cascade proteins linked to lipid metabolism dysregulation.
• Lipidomics and Metabolomics: Distinct lipid and metabolic profiles, such as disrupted bile acid and carbohydrate metabolism, serve as biomarkers and highlight the physiological impacts of DM on TB. See also: Scholarships Tips

---

2. Epidemiology and Public Health Strategies

• Prevalence and Risk Factors: DM prevalence among TB patients is influenced by age, lifestyle, socio-economic status, and hypertension, requiring molecular epidemiology to tailor public health strategies.
• Regional Variations: Disparities in TB-DM comorbidity across regions underscore the need for targeted interventions.
• Integrated Health Approaches: Proposed strategies include reciprocal TB and DM screening, addressing multimorbidities, and enhancing transmission dynamics research.
• WHO SEAR Data: In 2021, TB incidence was 234 per 100,000 population, with 38% undiagnosed/unreported cases and 763,000 deaths among HIV-negative individuals.

---

3. Socioeconomic and Environmental Impacts

• Economic Burden: Families in Southeast Asia face catastrophic costs (30%-80%) due to TB, highlighting the need for sustainable funding.
• Housing and Sanitation: Inadequate housing slightly affects TB treatment outcomes, while sanitation shows no direct correlation.
• Regional Initiatives: Strategies include domestic funding, digital technology, and multisectoral approaches targeting TB elimination by 2025-2030.
• Global Collaboration: Enhanced donor funding, public-private partnerships, and results-based financing are critical to addressing TB's socioeconomic impact.

---

4. Clinical and Technological Advancements

• Diagnostics and Treatment: Advances in rapid molecular diagnostics and digital X-rays have improved TB treatment coverage (78% by 2019).
• Single-Cell Analysis: Emerging technologies offer insights into immune dysfunction in TB-DM, identifying therapeutic targets and biomarkers.
• Predictive Tools: Integration of genetic, molecular, and clinical data supports the development of risk scores and precision medicine approaches.
• Vaccines: Research focuses on targeted TB vaccines for immunocompromised populations.

---

5. Challenges in TB Elimination and Patient Management

• Barriers to Care: Stigma, resource shortages, and inefficiencies in TB programs hinder early diagnosis and treatment adherence.
• Recurrent TB and Risk Factors: Irregular medication use, poor HbA1C control, and multiple TB episodes increase retreatment risk, especially in diabetic patients.
• Comorbidity Impact: Non-TB factors like age, renal disease, and cancer contribute to TB mortality, emphasizing holistic patient management.
• Policy Alignment: Coordinating local strategies with national and global goals enhances scalability and sustainability in TB control programs.

References:

1. Araujo-Pereira, M., Vinhaes, C.L., Barreto-Duarte, B., Villalva-Serra, K., Queiroz, A.T.L., & Andrade, B.B. (2024). Intersecting epidemics: Deciphering the complexities of tuberculosis-diabetes comorbidity. Frontiers in Tuberculosis, 2, Article 1487793.
2. Handayani, S. and Isworo, S., 2024. Evaluation of Tuberculosis program implementation in Primary Health Care, Semarang, Indonesia. International Journal of Public Health Asia Pacific, pp.1-11.
3. Hakam, M.A., Safitri, B.D., Wandastuti, A.D., Husni, M.F., Setiawan, A.W., Konoralma, A.R., Radja, B.L., Setiono, O. and Wulan, W.R., 2024. The Relationship Between Adequate Housing And Household Sanitation With The Success Of Tuberculosis Patient Treatment In Semarang City. International Journal of Health Literacy and Science, 2(2), pp.14-19.
4. Bhatia, V., Rijal, S., Sharma, M., Islam, A., Vassall, A., Bhargava, A., Thida, A., Basri, C., Onozaki, I., Pai, M. and Rezwan, M.K., 2023. Ending TB in South-East Asia: flagship priority and response transformation. The Lancet Regional Health-Southeast Asia, 18.
5. Bhatia V, Srivastava R, Reddy KS, et al. Ending TB in Southeast Asia: current resources are not enough. BMJ Global Health 2020;5:e002073.
6. Iskandar, D., Suwantika, A.A., Pradipta, I.S., Postma, M.J. and van Boven, J.F., 2023. Clinical and economic burden of drug-susceptible tuberculosis in Indonesia: national trends 2017–19. The Lancet Global Health, 11(1), pp.e117-e125.
7. Habib, M.A., Afrin, K., Efa, S.S., Hossain, M.D., Islam, M.R., Rahman, M.M., Islam, N., Afroz, F., Rahim, M.A. and Hossain, M.D., 2024. Effects of diabetes mellitus on retreatment of Tuberculosis: A multi-centered case-control study from Bangladesh. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 36, p.100450.
8. Chaw L, Jeludin NH, Thu K. Prevalence and risk factors associated with tuberculosis mortality in Brunei Darussalam. Asian Pac J Trop Med 2023; 16(1): 9-15.
9. Adam, N., Pallikadavath, S., Cerasuolo, M. and Amos, M., 2021. Investigating the risk factors for contraction and diagnosis of human tuberculosis in Indonesia using data from the fifth wave of RAND’s Indonesian Family Life Survey (IFLS-5). Journal of Biosocial Science, 53(4), pp.577-589.

TBC 038